Wnt Signalling Modulates Transcribed-ultraconserved Regions in Hepatobiliary Cancers
Overview
Authors
Affiliations
Objective: Transcribed-ultraconserved regions (T-UCR) are long non-coding RNAs which are conserved across species and are involved in carcinogenesis. We studied T-UCRs downstream of the Wnt/β-catenin pathway in liver cancer.
Design: Hypomorphic Apc mice () and thiocetamide (TAA)-treated rats developed Wnt/β-catenin dependent hepatocarcinoma (HCC) and cholangiocarcinoma (CCA), respectively. T-UCR expression was assessed by microarray, real-time PCR and in situ hybridisation.
Results: Overexpression of the T-UCR uc.158- could differentiate Wnt/β-catenin dependent HCC from normal liver and from β-catenin negative diethylnitrosamine (DEN)-induced HCC. uc.158- was overexpressed in human HepG2 versus Huh7 cells in line with activation of the Wnt pathway. In vitro modulation of β-catenin altered uc.158- expression in human malignant hepatocytes. uc.158- expression was increased in -mutated human HCCs compared with non-mutated human HCCs, and in human HCC with nuclear localisation of β-catenin. uc.158- was increased in TAA rat CCA and reduced after treatment with Wnt/β-catenin inhibitors. uc.158- expression was negative in human normal liver and biliary epithelia, while it was increased in human CCA in two different cohorts. Locked nucleic acid-mediated inhibition of uc.158- reduced anchorage cell growth, 3D-spheroid formation and spheroid-based cell migration, and increased apoptosis in HepG2 and SW1 cells. miR-193b was predicted to have binding sites within the uc.158- sequence. Modulation of uc.158- changed miR-193b expression in human malignant hepatocytes. Co-transfection of uc.158- inhibitor and anti-miR-193b rescued the effect of uc.158- inhibition on cell viability.
Conclusions: We showed that uc.158- is activated by the Wnt pathway in liver cancers and drives their growth. Thus, it may represent a promising target for the development of novel therapeutics.
Jiang Y, Liao C, Lai J, Peng Y, Chen Q, Zheng X Sci Rep. 2025; 15(1):6951.
PMID: 40011455 PMC: 11865440. DOI: 10.1038/s41598-024-84129-1.
Mei Q, Zhang Y, Li H, Ma W, Huang W, Wu Z Cell Death Differ. 2025; .
PMID: 39972058 DOI: 10.1038/s41418-025-01460-4.
Giron-Michel J, Padelli M, Oberlin E, Guenou H, Duclos-Vallee J BioDrugs. 2025; 39(2):237-260.
PMID: 39826071 PMC: 11906529. DOI: 10.1007/s40259-024-00702-0.
Xu P, Xi Y, Kim J, Zhu J, Zhang M, Xu M Acta Pharm Sin B. 2024; 14(3):1241-1256.
PMID: 38487006 PMC: 10935170. DOI: 10.1016/j.apsb.2023.12.006.
He J, Li W, Zhao W, Shen H, Chang Y, Liu B Heliyon. 2024; 10(2):e24453.
PMID: 38312553 PMC: 10835266. DOI: 10.1016/j.heliyon.2024.e24453.